Clinical Trial: NCT06400225
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-15 |
Study Overview
Brief Summary
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes. BVD-523FB (ulixertinib) is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of proteins that signal cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biopsy Procedure
- Procedure: Biospecimen Collection
- Procedure: Computed Tomography
- Procedure: Echocardiography Test
- Procedure: Magnetic Resonance Imaging
- Procedure: Radionuclide Imaging
- Drug: Ulixertinib
Other Study ID Numbers
- NCI-2024-01160
- NCI-2024-01160
- EAY131-Z1L
- EAY131-Z1L
- U10CA180820
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-15 |
Study Overview
Brief Summary
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes. BVD-523FB (ulixertinib) is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a class of medications called kinase inhibitors. It works by blocking the action of proteins that signal cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biopsy Procedure
- Procedure: Biospecimen Collection
- Procedure: Computed Tomography
- Procedure: Echocardiography Test
- Procedure: Magnetic Resonance Imaging
- Procedure: Radionuclide Imaging
- Drug: Ulixertinib
Other Study ID Numbers
- NCI-2024-01160
- NCI-2024-01160
- EAY131-Z1L
- EAY131-Z1L
- U10CA180820